Loading
Nurix Therapeutics, Inc. Stock: price and insider trades · United States
Nurix Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Nurix Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 9 insiders published 69 filings.
There is no open-market purchase to report; the filings show 23 sales worth €2.2M by 4 insiders. No amount is published for 2 filings, which the totals therefore leave out. At €472k, the sale published on 14 October 2026 by Gregory Julia P is the largest of the period (0.023% of market cap).
Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 69 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed no purchases and 34 sales. The 10-K for the year ended 30 November 2025 shows 84.0 m USD of revenue and -264.5 m USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
174
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
34 ops. · all time
Who traded when
BuySaleChristine Ring9 sales
Hans van Houte9 sales
Gwenn Hansen8 sales
Julia P. Gregory1 sale
Analyst consensus: bullish or bearish?
Analysts rate Nurix Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$34.36.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended November 2025 · cache
US$23.67
Analyst consensus
14 analystsStrong buy
US$25.00Target US$34.36(+45%)US$45.00
Income statement
RevenueUS$84M
EBITDA-US$266.8M-318% margin
Net income-US$264.5M42.0% margin
Valuation
PER (trailing)9.7x
PER (forward)-33.7x
P/Book2.7x
Beta1.82
Balance sheet & cash
Market capUS$2.6B
Total debtUS$55.7M
Free Cash Flow-US$263.5M
Debt / Equity7%
Profitability & ownership
ROE44.0%
ROA21.1%
% insiders1.1%
% institutions114.9%
Last declaration on 15 October 2026
Declarations174 total
1,452 shares@ US$1.860.0001% mcap0.5% of flowCommon StockSEC:0001817160-26-000021:0
1,452 shares@ US$25.000.0014% mcap7.3% of flowCommon StockSEC:0001817160-26-000021:1
22,583 shares@ US$23.40380.020% mcap100.0% of flowCommonSEC144:0001950047-26-010217
22,583 shares@ US$1.860.0018% mcap7.1% of flowCommon StockSEC:0001226675-26-000006:0
22,583 shares@ US$23.40380.023% mcap89.7% of flowCommon StockSEC:0001226675-26-000006:1
5,786 shares@ US$23.340.0057% mcap11.3% of flowCommonSEC144:0001950047-26-010001
5,786 shares@ US$8.720.0021% mcap3.2% of flowCommon StockSEC:0001817199-26-000032:0
5,786 shares@ US$23.18510.0055% mcap8.5% of flowCommon StockSEC:0001817199-26-000032:1
1,452 shares@ US$25.470.0015% mcap7.8% of flowCommon StockSEC:0001817160-26-000019:1
1,452 shares@ US$1.860.0001% mcap0.6% of flowCommon StockSEC:0001817160-26-000019:0
8,712 shares@ US$24.690.0086% mcap100.0% of flowCommonSEC144:0001950047-26-007704
1,500 shares@ US$23.86840.0014% mcap7.7% of flowCommon StockSEC:0001817160-26-000015:0
2,611 shares@ US$24.64150.0026% mcap13.8% of flowCommon StockSEC:0001817160-26-000015:1
4,356 shares@ US$1.860.0003% mcap1.7% of flowCommon StockSEC:0001817160-26-000017:0
4,356 shares@ US$25.000.0043% mcap23.3% of flowCommon StockSEC:0001817160-26-000017:1
4,111 shares@ US$23.220.0040% mcap47.5% of flowCommonSEC144:0001950047-26-007639
4,761 shares@ US$23.220.0046% mcap100.0% of flowCommonSEC144:0001950047-26-007637
1,794 shares@ US$23.89110.0017% mcap2.2% of flowCommon StockSEC:0001817217-26-000012:0
2,967 shares@ US$24.64740.0029% mcap3.7% of flowCommon StockSEC:0001817217-26-000012:1
16,589 shares@ US$23.210.016% mcap35.2% of flowCommonSEC144:0001950047-26-007550
16,589 shares@ US$23.04890.015% mcap26.9% of flowCommon StockSEC:0001817199-26-000028:1
5,787 shares@ US$8.720.0020% mcap3.5% of flowCommon StockSEC:0001817199-26-000028:0
3,750 shares0Common StockSEC:0001817160-26-000012:0
3,572 shares0Common StockSEC:0001817199-26-000026:2
2,858 shares0Common StockSEC:0001817160-26-000012:1
25 of 174 declarations
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (ticker: NRIX) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. For investors, Nurix is best understood as a clinical-stage biotech focused on a highly specialized and potentially disruptive scientific approach: targeted protein degradation. Rather than merely blocking disease-related proteins, Nurix seeks to eliminate them inside the cell. That distinction matters because it can open therapeutic opportunities against targets that have historically been difficult to address with conventional small molecules. As a clinical-stage company, Nurix’s value proposition is still driven primarily by scientific execution, clinical data, and partnering potential rather than by product sales. ([ir.nurixtx.com](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2025?utm_source=openai))
The company was founded on research showing that protein levels inside cells can be selectively altered, and its core platform combines expertise in E3 ligases with its proprietary DELigase discovery engine. This platform is central to its competitive position: it is designed to identify and advance drug candidates across difficult target classes and supports Nurix’s strategy of building a pipeline around induced proximity pharmacology. In investor terms, that gives the company a differentiated scientific moat, although it remains subject to the usual biotech risks of clinical failure, regulatory uncertainty, and capital needs. ([ir.nurixtx.com](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-outlines-2025-goals-and-objectives?utm_source=openai))
Read moreShow less
Nurix’s portfolio is concentrated in oncology and autoimmune/inflammatory disease. Its lead clinical asset, bexobrutideg (NX-5948), is an oral, brain-penetrant BTK degrader that has become a key focal point for the company’s late-stage strategy in B-cell malignancies. Beyond that, Nurix is also advancing partnered and internal programs such as GS-6791 with Gilead in autoimmune disease and a STAT6 degrader program with Sanofi. The company has additionally highlighted preclinical work in targets such as pan-mutant BRAF, CBL-B, and AURKA, underscoring the breadth of its platform and the potential to extend beyond a single lead asset. ([ir.nurixtx.com](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-reports-first-quarter-2026-financial-results/?utm_source=openai))
Nurix is headquartered in the San Francisco Bay Area, in California, United States, and its geographic footprint is still largely research-driven rather than commercial. It does not yet have a marketed-product footprint comparable to large-cap pharmaceutical peers; instead, its international presence is mainly reflected through collaborations with major pharma partners and scientific presentations at global medical conferences in the U.S. and Europe. Those partnerships are strategically important because they can provide external validation, milestone revenue, and a lower-cost route to broadening the pipeline. ([ir.nurixtx.com](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-reports-second-quarter-2025-financial-results?utm_source=openai))
Recent milestones have reinforced the company’s momentum. In 2025 and 2026, Nurix reported encouraging clinical updates for bexobrutideg, outlined 2026 objectives centered on advancing that program toward pivotal development, and presented new preclinical data at AACR 2026 showcasing the breadth of its targeted protein degradation pipeline. The company also continued to advance strategic collaborations and board-level strengthening. Overall, Nurix remains a high-risk, high-upside NASDAQ-listed biotech in the United States, with the investment case tied to clinical execution, partnership economics, and the eventual translation of its platform into approved medicines. ([ir.nurixtx.com](https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
